NON-ANTIBIOTIC USE OF ANTIBIOTICS

1.Abbaszadeh A., Darabi S., Hasanvand A., Amini-Khoei H., Abbasnezhad A., Choghakhori R., Aaliehpour A.: Minocycline through attenuation of oxidative stress and inflammatory response reduces the neuropathic pain in a rat model of chronic constriction injury. Iran. J. Basic Med. Sci. 21, 138–144 (2018)Search in Google Scholar

2.Bajaj J.S., Gillevet P.M. i wsp.: Modulation of the microbiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE,8, e60042 (2013)10.1371/journal.pone.0060042Search in Google Scholar

3.Banh H.L.: Unconventional treatment options in severe asthma: an overview. J. Pharm. Pharm. Sci. 14, 387–399 (2011)Search in Google Scholar

4.Beker B., Mujica V., Guelrud M.: Effect of erythromycin on the sphincter of Oddi in healthy volunteers. Gastroenterology, 100, A309 (1991)Search in Google Scholar

5.Broad J., Sanger G.J.: The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Brit. J. Pharmacol. 168, 1859–1867 (2013)Search in Google Scholar

6.Calanni F., Renzulli C., Barbanti M., Viscomi G.C.: Rifaximin: beyond the traditional antibiotic activity. J. Antibiot. 67, 667– 670 (2014)10.1038/ja.2014.106Search in Google Scholar

7.Carbonell N., Pauwels A., Serfaty L., Boelle P.Y., Becquemont L, Poupon R: Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am. J. Gastroenterol. 101, 1211–1215 (2006)10.1111/j.1572-0241.2006.00582.xSearch in Google Scholar

8.Carsenti-Dellamonica H., Galimand M., Vandenbos F., Pradier C., Roger P.M., Dunais B., Sabah M., Mancini G., Dellamonica P.: In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G and macrolides. J. Antimicrob. Chemother. 56, 633–642 (2005)10.1093/jac/dki301Search in Google Scholar

9.Catnach S.M., Fairclough P.D., Trembath R.C., O’Donnell L.J.D., McLean A.M., Law P.A., Wickham J.E.A.: Effect of oral erythromycin on gallbladder motility in normal and gallstone subjects. Gastroenterology, 102, 2071–2076 (1992)10.1016/0016-5085(92)90334-USearch in Google Scholar

10.Cheng J., Shah Y.M., Gonzalez F.J.: Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol. Sci. 33, 323–330 (2012)Search in Google Scholar

11.Cherrill D.A., Stote R.M., Birge J.R., Singer I.: Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann. Int. Med. 83, 654–656 (1975)Search in Google Scholar

12.Chini P., Toskes P.P., Waseem S., Hou W., McDonald R., Moshiree B.: Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand. J. Gastroenterol. 47, 422–427 (2012)Search in Google Scholar

13.Choi Y., Suh Y.H. i wsp.: Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. Neuropsychopharmacology, 32, 2393–2404 (2007)10.1038/sj.npp.130137717406652Search in Google Scholar

14.Coffin B., Valleur P. i wsp.: Erythromycin improves the quality of EGD in patients with acute upper GI bleeding: a randomized controlled study. Gastrointest. Endosc. 56, 174–179 (2002)Search in Google Scholar

15.Curry J.I., Lander T.D., Stringer M.D.: Review article: erythromycin as a prokinetic agent in infants and children. Aliment. Pharmacol. Ther. 15, 595–603 (2001)Search in Google Scholar

16.Dall’Antonia M., Wilks M., Coen P.G., Bragman S., Millar M.R.: Erythromycin for prokinetics: imprudent prescribing? Crit. Care, 10, 112 (2006)10.1186/cc3956155083516420656Search in Google Scholar

17.De Francesco E.M., Bonuccelli G., Maggiolini M., Sotgia F., Lisanti M.P.: Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). Oncotarget, 40, 67269–67286 (2017)10.18632/oncotarget.18428562017228978032Search in Google Scholar

18.De Francesco E.M., Maggiolini M., Tanowitz H.B., Sotgia F., Lisanti M.P.: Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy. Oncotarget, 34, 56126–56142 (2017)10.18632/oncotarget.18445559354928915578Search in Google Scholar

19.Demoly P., Gueron B., Annunziata K., Adamek L., Walters R.D.: Update on asthma control in five European countries: results of a 2008 survey. Eur. Respir. Rev. 116, 150–157 (2010)10.1183/09059180.0000211020956184Search in Google Scholar

20.Depoortere I., Peeters T.L., Matthijs G., Vantrappen G.: Macrolides antibiotics are motilin receptor agonists. Hepatogastroen-terology, 35, 198 (1988)Search in Google Scholar

21.Doherty W.L., Winter B.: Prokinetic agents in critical care. Crit. Care, 7, 206–208 (2003)Search in Google Scholar

22.Fox C., Dingman A., Derugin N., Wendland M.F., Manabat C., Ji S., Ferriero D.M., Vexler Z.S.: Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J. Cereb. Blood Flow Metab. 25, 1138–1149 (2005)10.1038/sj.jcbfm.9600121226209715874975Search in Google Scholar

23.Frossard J.L., Spahr L., Queneau P.E., Giostra E., Burckhardt B., Ory G., De Saussure P., Armenian B., De Peyer R., Hadengue A.: Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double blind trial. Gastroenterology, 123, 17–23 (2002)10.1053/gast.2002.3423012105828Search in Google Scholar

24.German-Fattal M.: Fusafungine, an antimicrobial with anti-inflammatory properties in respiratory tract infections – review and recent advances in cellular and molecular activity. Clin. Drug Investig. 21, 653–670 (2001)10.2165/00044011-200121090-00007Search in Google Scholar

25.Goh K.P.: Management of hyponatremia. Am. Fam. Physician, 69, 2387–2394 (2004)Search in Google Scholar

26.Golub L.M., Goodson J.M., Lee H.M., Vidal A.M., McNamara T.F., Ramamurthy N.S.: Tetracyclines Inhibit Tissue Collagenases: Effects of Ingested Low-Dose and Local Delivery Systems. J. Periodontol. 56, 93–97 (1985)10.1902/jop.1985.56.11s.933001266Search in Google Scholar

27.Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., Sorsa T.: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 12, 12–26 (1998)Search in Google Scholar

28.Golub L.M., McNamara T.F., Ryan M.E., Kohut B., Blieden T., Payonk G., Sipos T., Baron H.J.: Adjunctive treatment with subantimicrobial doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in adult periodontitis. J. Clin. Periodontol. 28, 146–156 (2001)10.1034/j.1600-051x.2001.028002146.x11168739Search in Google Scholar

29.Gu Y., Lee H.M., Sorsa T., Simon S.R., Golub L.M.: Doxycycline inhibits mononuclear cell-mediated connective tissue breakdown. FEMS Immunol. Med. Microbiol. 58, 218–225 (2010)Search in Google Scholar

30.Hahn D.L., Grasmick M., Hetzel S., Yale S.: Azithromycin for bronchial asthma in adults: an effectiveness trial. J. Am. Board Fam. Med. 25, 442–459 (2012)Search in Google Scholar

31.Hahn D.L., Plane M.B., Mahdi O.S., Byrne G.I.: Secondary Outcomes of a Pilot Randomized Trial of Azithromycin Treatment for Asthma. PLoS Clin. Trials, 2, e11, (2006)Search in Google Scholar

32.Hatipoglu U., Rubinstein I.: Low-dose, long-term macrolide therapy in asthma: An overview. Clin. Mol. Allergy, 2, 4 (2004)Search in Google Scholar

33.Hu Y.Y., Xu J., Zhang M., Wang D., Li L., Li W.B.: Ceftriaxone modulates uptake activity of glial glutamate transporter-1 against global brain ischemia in rats. J. Neurochem. 132, 194–205 (2015)10.1111/jnc.1295825270764Search in Google Scholar

34.Itoh Z., Nakaya M., Suzuki T., Arai H., Wakabayashi K.: Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am. J. Physiol. 247, G688–694 (1984)10.1152/ajpgi.1984.247.6.G6886507625Search in Google Scholar

35.Jalal F.Y., Yang Y., Thompson J.F., Roitbak T., Rosenberg G.A.: Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP. J. Cereb. Blood Flow Metab. 35, 1145–1153 (2015)10.1038/jcbfm.2015.21464026525712499Search in Google Scholar

36.Janssens J., Vantrappen G., Annese V., Peeters T.L., Tijskens G., Rekoumis G.: Effect of erythromycin on LES function and oesophageal body contractility. Gastroenterology, 98, A64 (1990)Search in Google Scholar

37.Jesionowska A., Cecerska-Heryć E., Marczuk N., Safronow K., Dołęgowska B.: Kwas lizofosfatydowy w nowotworach złośliwych. Postępy Biochemii, 4, 381–387 (2015)Search in Google Scholar

38.Jiang Z.D., Ke S., DuPont H.L.: Rifaximin-induced alteration of virulence of diarrhea-producing Escherichia coli and Shigella sonnei. Int. J. Antimicrob. Agents, 35, 278–281 (2010)10.1016/j.ijantimicag.2009.11.01320045287Search in Google Scholar

39.John R., Brazier J.S.: Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J. Hosp. Infect. 61, 11–14 (2005)10.1016/j.jhin.2005.01.02016002183Search in Google Scholar

40.Johnston S.L., Chauhan A. i wsp.: Azithromycin for Acute Exacerbations of Asthma: The AZALEA Randomized Clinical Trial. JAMA Intern. Med. 176, 1630–1637 (2016)Search in Google Scholar

41.Kajander K., Myllyluoma E., Kyrönpalo S., Rasmussen M., Sipponen P., Mattila I., Seppänen-Laakso T., Vapaatalo H., Oresic M., Korpela R.: Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J. Gastroenterol. 15, 6068–6074 (2009)Search in Google Scholar

42.Kalambokis G.N., Mouzaki A., Rodi M., Pappas K., Fotopoulos A., Xourgia X., Tsianos E.V.: Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815–818 (2012)Search in Google Scholar

43.Kew K.M., Undela K., Kotortsi I., Ferrara G.: Macrolides for chronic asthma. Cochrane Database Syst. Rev. 9, CD002997 (2015)10.1002/14651858.CD002997.pub426371536Search in Google Scholar

44.Kliewer S.A., Goodwin B., Willson T.M.: The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23, 687–702 (2002)10.1210/er.2001-003812372848Search in Google Scholar

45.Krzyżanowska W., Pomierzy B., Budziszewska B., Filip M., Pera J.: N-Acetylcysteine and Ceftriaxone as Preconditioning Strategies in Focal Brain Ischemia: Influence on Glutamate Transporters Expression. Neurotox. Res. 29, 539–550 (2016)10.1007/s12640-016-9602-z482048326861954Search in Google Scholar

46.Ksiądzyna D.: Zaburzenia czynnościowe żołądka i dwunastnicy (w) Zaburzenia czynnościowe przewodu pokarmowego, red. L. Paradowski, Cornetis, Wrocław, 2012, s. 89–104Search in Google Scholar

47.Ksiądzyna D.: Wpływ innych chorób na czynność przewodu pokarmowego – gastropareza (w) Zaburzenia czynnościowe przewodu pokarmowego, red. L. Paradowski, Cornetis, Wrocław, 2012, s. 213–227Search in Google Scholar

48.Lee G.J., Lim J.J., Hyun S.: Minocycline treatment increases resistance to oxidative stress and extends lifespan in Drosophila via FOXO. Oncotarget, 50, 87878–87890 (2017)10.18632/oncotarget.21224567567929152127Search in Google Scholar

49.Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B.: Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 283, 13116–13123 (2008)Search in Google Scholar

50.Lehtola J., Jauhonen P., Kesaniemi A., Wikberg R., Gordin A.: Effect of erythromycin on the oro-caecal transit time in man. Eur. J. Clin. Pharmacol. 39, 555–558, (1990)10.1007/BF003160942095341Search in Google Scholar

51.Leung T.C.H., Lui C.N.P., Chen L.W., Yung W.H., Chan Y.S., Yung K.K.L.: Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem. Neurosci. 3, 22–30 (2012)Search in Google Scholar

52.Leung W.K., Chan F.K.L., Fung S.S.L., Wong M.Y., Sung J.J.Y.: Effect of oral erythromycin on gastric and small bowel transit time of capsule endoscopy. World J. Gastroenterol.11, 4865–4868 (2005)10.3748/wjg.v11.i31.4865439873816097060Search in Google Scholar

53.Lewerenz J., Albrecht P., Tien M.L., Henke N., Karumbayaram S., Kornblum H.I., Wiedau-Pazos M., Schubert D., Maher P., Methner A.: Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 111, 332–243 (2009)10.1111/j.1471-4159.2009.06347.x19694903Search in Google Scholar

54.Liebregts T., Holtman G. i wsp.: Immune activation in patients with irritable bowel syndrome. Gastroenterology, 132, 913–920 (2007)10.1053/j.gastro.2007.01.04617383420Search in Google Scholar

55.Lund V.J., Grouin J.M., Eccles R., Bouter C., Chabolle F.: Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis. Rhinology, 42, 207–212 (2004)Search in Google Scholar

56.Marek T., Baniukiewicz A., Wallner G., Rydzewska G., Dąbrowski A.: Wytyczne postępowania w krwawieniu z górnego odcinka przewodu pokarmowego pochodzenia nieżylakowego. Prz. Gastroenterol. 3, 1–22 (2008)Search in Google Scholar

57.Matsumoto T., Uchiumi T., Monji K., Yagi M., Setoyama D., Amamoto R., Matsushima Y., Shiota M., Eto M., Kang D.: Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity. Oncogenesis, 11, 397 (2017)10.1038/s41389-017-0009-3586805829184058Search in Google Scholar

58.McGuire J.M., Bunch R.L., Anderson R.C., Boaz H.E., Flynn E.H., Powell H.M., Smith J.W.: "Ilotycin”, a new antibiotic. Antibiot. Chemother. 2, 281 (1952)Search in Google Scholar

59.Menzel M., Akbarshahi H., Tufvesson E., Persson C., Bjermer L., Uller L.: Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget, 19, 31601–31611 (2017)10.18632/oncotarget.16364545823328415826Search in Google Scholar

60.Mertens V., Blondeau K., Pauwels A., Farre R., Vanaudenaerde B., Vos R., Verleden G., Van Raemdonck D.E., Dupont L.J., Sifrim D.: Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig. Dis. Sci. 54, 972–979 (2009)Search in Google Scholar

61.Miell J., Dhanjal P., Jamookeeah C.: Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review. Int. J. Clin. Pract. 69, 1396–1417 (2015)10.1111/ijcp.12713504209426289137Search in Google Scholar

62.Min Y., Li F. i wsp.: Minocycline-Suppression of Early Peripheral Inflammation Reduces Hypoxia-Induced Neonatal Brain Injury. Front. Neurosci. 11, 511 (2017)10.3389/fnins.2017.00511560096228955196Search in Google Scholar

63.Moini-Zanjani T., Ostad S.N., Labibi F., Ameli H., Mosaffa N., Sabetkasaei M.: Minocycline Effects on IL-6 Concentration in Macrophage and Microglial Cells in a Rat Model of Neuropathic Pain. Iran. Biomed. J. 20, 273–279 (2016)Search in Google Scholar

64.Mullany P., Wilks M., Tabaqchali S.: Transfer of macrolide-lincosamide – streptogramin B (MLS) resistance in Clostridium difficile is linked to a gene homologous with toxin A and is mediated by a conjugative transposon Tn5398. J. Antimicrob. Chemother. 35, 305–315 (1995)10.1093/jac/35.2.3057759394Search in Google Scholar

65.Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., Vantrappen G.: Erythromycin is a motilin receptor agonist. Am. J. Physiol. 257, G470–G474 (1989)10.1152/ajpgi.1989.257.3.G4702782416Search in Google Scholar

66.Peiris-Pagès M., Sotgia F., Lisanti M.P.: Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience, 8, 696–699 (2015)10.18632/oncoscience.215458006226425660Search in Google Scholar

67.Pietrzak A., Bartnik W., Szczepkowski M., Krokowicz P., Dziki A., Reguła J., Wallner G.: Polish interdisciplinary consensus on diagnostics and treatment of colonic diverticulosis. Pol. Przeg. Chir. 87, 203–220 (2015)Search in Google Scholar

68.Pilot M.A., Ritchie H.D., Thompson H., Zara G.P.: Alterations in gastrointestinal motility associated with erythromycin. Br. J. Pharmacol. 81: 168P (1984)Search in Google Scholar

69.Pimentel M., Forbes W.P. i wsp.: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364, 22–32 (2011)Search in Google Scholar

70.Pimentel M.: Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment. Pharmacol. Ther. 43Suppl. 1, 37–49 (2016)Search in Google Scholar

71.Pimentel M., Cash B.D., Limbo A., Wolf R.A., Israel R.J., Schoenfeld P.: Repeat rifaximin for irritable bowel syndrome: no clinical significant changes in stool microbial antibiotic sensitivity. Dig. Dis. Sci. 62, 2455–2463 (2017)Search in Google Scholar

72.Qin Y., Zhou H.G. i wsp.: Doxycycline reverses epithelial-to-me-senchymal transition and suppresses the proliferation and metastasis of lung cancer cells. Oncotarget, 38, 40667–40679 (2015)Search in Google Scholar

73.Reiter J., Demirel N., Mendy A., Gasana J., Vieira E.R., Colin A.A., Quizon A., Forno E.: Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy, 68, 1040–1049 (2013)10.1111/all.1219923895667Search in Google Scholar

74.Richards R.D., Davenport K.G., Hurm K.D., Wimbish W.R., McCallum R.W.: Acute and chronic treatment of gastroparesis with erythromycin. Gastroenterology, 98, A385 (1990)Search in Google Scholar

75.Rifkin B.R., Vernillo A.T., Golub L.M.: Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs. Journal of Periodontology, 64, 819–827 (1993)10.1902/jop.1993.64.8s.8198410621Search in Google Scholar

76.Rohof W.O., Bennink R.J., Ruigh A.A., Hirsch D.P., Zwinderman A.H., Boeckxstaens G.E.: Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut, 61, 1670–1677 (2012)10.1136/gutjnl-2011-30092622267599Search in Google Scholar

77.Rothstein J.D., Fisher P.B. i wsp.: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 7021, 73–77 (2005)Search in Google Scholar

78.Ruzza P., Sechi G. i wsp.: Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem. Neurosci. 5, 30–38 (2014)Search in Google Scholar

79.Sarna S.K., Lee M.B. i wsp.: Effects of erythromycin on human gastrointestinal motor activity in the fed and fasted states. Gastroenterology, 96, A440 (1989)Search in Google Scholar

80.Scholz R., Sobotka M., Caramoy A., Stempfl A., Moehle C., Langmann T.: Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. J. Neuroinflammation, 12: 209 (2015)10.1186/s12974-015-0431-4465086626576678Search in Google Scholar

81.Secko D.: Antibiotics that protect the brain. CMAJ172, 467–468 (2005)10.1503/cmaj.05002254840415710934Search in Google Scholar

82.Sherlock M., Thompson C.J.: The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur. J. Endocrinol. 162Suppl. 1, S13–88 (2010)10.1530/EJE-09-1057Search in Google Scholar

83.Shlopov B.V., Stuart J.M., Gumanovskaya M.L., Hasty K.A.: Regulation of cartilage collagenase by doxycycline. J. Rheumatol. 28, 835–842 (2001)Search in Google Scholar

84.Smith G.N. Jr., Yu L.P. Jr., Brandt K.D., Capello W.N.: Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J. Rheumatol. 25, 532–535 (1998)Search in Google Scholar

85.Sorsa T., Tervahartiala T., Leppilahti J., Hernandez M., Gamonal J., Tuomainen A.M., Lauhio A., Pussinen P.J., Mäntylä P.: Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol. Res. 63, 108–113 (2011)10.1016/j.phrs.2010.10.005Search in Google Scholar

86.Spasovski G., Nagler E. i wsp.: Clinical practice guidelines on diagnosis and treatment of hyponatremia. Eur. J. Endocrinol. 170, G1–47 (2014)10.1530/EJE-13-1020Search in Google Scholar

87.Stallinger S., Eller N., Högenauer C.: Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wiener Klin. Wochenschr. 126, 9–14 (2014)Search in Google Scholar

88.Sturm A., Holtmann G., Goebell H., Gerken G.: Prokinetics in patients with gastroparesis: a systematic analysis. Digestion, 60, 422–427 (1999)10.1159/000007687Search in Google Scholar

89.Sy-Cordero A.A., Pearce C.J., Oberlies N.H.: Revisiting the enniatins: a revive of their isolation, biosynthesis, structure determination, and biological activities. J. Antibiot. 65, 541–549 (2012)10.1038/ja.2012.71Search in Google Scholar

90.Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., Mack R.J.: Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double blind, placebo controlled trial. Gut, 49, 395–401 (2001)10.1136/gut.49.3.395Search in Google Scholar

91.Tang X., Wang X., Zhao Y.Y., Curtis J.M., Brindley D.N.: Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation. Mol. Cancer, 16, 36 (2017)10.1186/s12943-017-0607-xSearch in Google Scholar

92.Vezina C., Kudelski A., Sehgal S.N.: Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing strep-tomycete and isolation of the active principle. J. Antibiot. 28, 721–726 (1975)10.7164/antibiotics.28.721Search in Google Scholar

93.Wang Z., Nong J., Shultz R.B., Zhang Z., Kim T., Tom V.J., Ponnappan R.K., Zhong Y.: Local delivery of minocycline from metal ion-assisted self-assembled complexes promotes neuroprotection and functional recovery after spinal cord injury. Biomaterials, 112, 62–71 (2017)10.1016/j.biomaterials.2016.10.002Search in Google Scholar

94.Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., Frost E., McDonald L.C.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, 366, 1079–1084 (2005)10.1016/S0140-6736(05)67420-XSearch in Google Scholar

95.Webley W.C., Hahn D.L.: Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. Respiratory Res. 18, 98 (2017)10.1186/s12931-017-0584-z543765628526018Search in Google Scholar

96.Xu X., Gaggar A. i wsp.: Doxycycline improves clinical outcomes during cystic fibrosis exacerbations. Eur. Respir. J. 49, pii: 1601102 (2017)10.1183/13993003.01102-201628381428Search in Google Scholar

97.Zatmann T.F., Hall J.E., Harmer M.: Gastric residual volume in children: a study comparing efficiency of erythromycin and metoclopramide as prokinetic agents. Br. J. Anaesth. 86, 869–871 (2001)10.1093/bja/86.6.86911573597Search in Google Scholar

98.Zhang L., Xu L., Zhang F., Vlashi E.: Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle, 16, 737–745 (2017)10.1080/15384101.2016.1241929540572927753527Search in Google Scholar

99.Zhong W., Yang C. i wsp.: Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway. Oncotarget, 62, 104855-104866 (2017)Search in Google Scholar